VivoSeq
Oncology

HER2-Positive Breast Cancer

15

Pipeline Programs↗

5

Active Trials↗

9

Companies Involved↗

HER2-positive Breast Cancer is an emerging landscape with 15 programs across 9 companies. The most active players are Jazz Pharmaceuticals, Teva, Merck & Co.. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 2Teva logo

Teva

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2A

Avyxa

2 programs

Phase 3S

Sichuan Baili Pharmaceutical Co., Ltd.

1 program

Phase 3J

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

10 of 14 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody429%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 93% of 15 pipeline programs.

Analysis

Trial Status

8

clinical trials

Recruiting3 · 38%
Active, not recruiting2 · 25%
Completed2 · 25%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases
Recruiting·Roche logoRoche·Preclinical·NCT07413939·650 enrolled
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 2·NCT07102381·125 enrolled
A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane
Recruiting·GGeneQuantum Healthcare (Suzhou) Co., Ltd.·Phase 3·NCT07673029·228 enrolled
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)
Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT03747120·138 enrolled
A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.
Active, not recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06747338·520 enrolled
Real World Patient-Reported Outcomes in Chinese Her2+ Early Breast Cancer Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Completed·FFudan University·N/A·NCT06161922·600 enrolled
SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Using 99mTc-DARPinG3 in HER2-positive Breast Cancer Patients in Dynamic of Chemo+Targeted Therapy
Completed·TTomsk National Research Medical Center of the Russian Academy of Sciences·N/A·NCT05412459·15 enrolled
Monitoring Early Response to Targeted Therapy in Stage IV Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Patients With Advanced Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Withdrawn·UUniversity of Alabama at Birmingham·Preclinical·NCT04273555

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)